Myeloproliferative disorders in patients with inflammatory bowel disease on anti-TNF-α therapy: Report of two cases and review of the literature

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages 674-675

  Fischer, Monika ^a   Helper, Debra J ^a   Chiorean, Michael V ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANAGRELIDE; AZATHIOPRINE; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CASE REPORT; CELL PROLIFERATION; CHROMOSOME 16; CHROMOSOME ANALYSIS; CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; GRAFT VERSUS HOST REACTION; HUMAN; ILEOANAL ANASTOMOSIS; ILEUM POUCH; LETTER; LEUKEMIA CELL; MALE; MYELOPROLIFERATIVE DISORDER; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; MALE; MYELOPROLIFERATIVE DISORDERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651287114     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21291     Document Type: Letter

References (8)

1. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 8: 874-881.
2. Murase T, Hotta T, Saito H, et al. Effect of recombinant human tumour necrosis factor on the colony growth of human leukemia progenitor cells and normal haematopoetic progenitor cells. Blood. 1987; 69: 467-472.
3. Hu X, Tang M, Fisher AB, et al. TNF-α-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-κB activation. J Immunol. 1999; 163: 3106-3115.
4. Ferreira C, Bos CL, Versteeg HH, et al. Molecular mechanism of violacein-mediated human leukemia cell death. Blood. 2004; 104: 1459-1464.
5. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009; 30: 210-226.
6. Fidder H, Schnitzler, F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut. 2009; 58: 477-478.
7. Fast Stats: an interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed February 8, 2010.
8. Broussais F, Miossec P, Kawashima M, et al. Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Ann Rheum Dis. 2005; 64: 509-510.